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Objectives: antibodies against Chlamydia pneumoniae have been associated with atherosclerosis and with expansion of
abdominal aortic aneurysms (AAA). C. pneumoniae has been demonstrated in coronary arteries, AAA and the carotid
arteries by use of polymerase chain reactions (PCR), immunohistochemical procedures and electron microscopy. However,
the correlation between demonstrating C. pneumoniae DNA or antigen in tissue from plaque material or aneurysms and
the antibody titres in serum is controversial. The specificity of immunohistochemical procedures is unknown. The aim of
this study was to assess the possibility of potential non-specific findings for methods based on immunostaining.
Materials and methods: twenty patients undergoing infrarenal AAA repair were studied. Full AAA thickness tissue was
collected from the anterior wall of the aneurysm. Analysis was performed using polyacrylamide gelelectrophoresis,
immunoblotting and mass spectrometric protein identification.
Results: C. pneumoniae antigen was not demonstrated in any of the AAA samples, whereas a major cross-reacting
protein was present in all AAA samples. The protein was identified as the human haemoglobin beta chain.
Conclusion: we were not able to find C. pneumoniae antigens reacting with an anti C. pneumoniae major outer
membrane protein (MOMP). Direct detection of C. pneumoniae by immunohistostaining procedures should be inter-
preted with caution due to potential crossreaction with non chlamydial proteins.
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The widespread respiratory pathogen Chlamydia
pneumoniae has been associated with the expansion
of abdominal aortic aneurysms (AAA) and some sero-
epidemiological studies have shown associations with
atherosclerosis and acute myocardial infarction.1±8
Furthermore, C. pneumoniae has been demonstrated
in the atherosclerotic lesions of the coronary arteries,
the carotid arteries and in AAA by a variety of tests,
including immunohistochemical techniques, enzyme-
linked immunosorbent assay (ELISA), the polymerase
chain reaction (PCR), electron microscopy and isolation
in tissue culture.9±14 However, later meta-analysis15
showed no differences in antibody titers between
cases and controls, and detection rates of C. pneumo-
niae within atherosclerotic lesions by PCR vary
between 0% and 100%.16 Furthermore, the correlation
between demonstrating C. pneumoniae DNA or
antigen in tissue from aneurysms or plaque materialPlease address all correspondence to: S. Vammen, Jyllands Alle 131,
DK-8260 Viby J, Denmark.
1078±5884/02/010081  05 $35.00/0 # 2002 Elsevier Science Ltd. Aand the antibody titres in serum is controversy.17,18
The relationship between AAA, infection and athero-
sclerotic disease therefore remains unknown, and the
clinical impact of detecting the organism is unresolved.
C. pneumoniae has a complex antigenic structure due
to different components and proteins on the surface.19
To identify C. pneumoniae in the AAA wall we used
antibodies against recombinant major outer mem-
brane protein (MOMP).
The specificity of immunohistochemical procedures
is unknown. Thus, the aim of the study was to eva-
luate the specificity of direct detection by immuno-
blotting using antibodies against C. pneumoniae
recombinant MOMP.
Material and Methods
Patients
Twenty patients undergoing infrarenal AAA repair
between 1998 and 2000, because of symptomatic
AAA, at the Department of Vascular Surgery, Viborg
Hospital, were studied in the year 2001. Retrospectivell rights reserved.
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sion was obtained (Table 1). There were 19 male
patients and 1 female patient. The mean age was
71.9 years and the age range 46±85 years. The maximal
cross-sectional diameter of the AAA was measured by
ultrasound and/or computed tomography scanning
carried out immediately before the operation.
The study was approved by the local scientific
ethics committee and reported to the data protection
authorities. All patients gave informed consent.
Specimen sampling and tissue preparation
Full AAA thickness tissue were collected from the
anterior wall of the aneurysm and stored immediately
at ÿ22 C. Approximately 1 g was rinsed three times
with PBS buffer (2.7 mM KCl, 1.8 mM KH2PO4,
10.1 mM Na2HPO4, 140 mM NaCl, pH 7.0) for 10 min.
The specimens were crushed in a 1 ml cold sucrose
buffer (300 mM sucrose, 10 mM Tris at pH 7.4), con-
taining the protease inhibitors 1 mM Na-EDTA, 1 mM
PMSF, 1 mM pepstatin and 1 mM leupeptin, by an
Ultra-Turax homogenisator. Cell debris was removed
by centrifugation (14 000g for 20 min). Clear protein
solutions were used for subsequent gelelectrophoresis.Fig. 1. SDS-PAGE and silverstaining of AAA proteins obtained from 2
Table 1. Patient characteristics.
(n 20)
Gender: Males/Females 19/1
Age (years) Median (range) 71 (46±85)
Aneurysm diameter > 6 cm 5 (25%)
Current smoker 17 (85%)
Arterial hypertension 8 (40%)
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The total AAA protein content of each sample were
estimated by Bio-Rad Protein Assay (Hercules, CA,
U.S.A.) based on the method of Bradford.20 Approxi-
mately 25 mg of prepared sample was loaded in each
well and run on 10±20% gradient polyacrylamide
minigels (NOVEX, San Diego, CA, U.S.A.). Before
blotting the quality of the protein samples, with spe-
cial reference to protein degradation, they were ana-
lysed by SDS-PAGE and silver stained gels using the
method of TunoÂn and Johansson21 (Fig. 1). After trans-
fer by electroelution to nitrocellulose membranes, blots
were blocked for 1 h with 0.5% milk in phosphate-
buffer saline (PBS)-Tris (2.7 mM KCl, 1.8 mM KH2PO4,
10.1 mM Na2HPO4, 140 mM NaCl, 0.05% Tween-20
[pH 7.0]) and incubated with anti-MOMP antibody
diluted 1:100 at room temperature for 1 h. The anti-
MOMP antibody was PAb 116 against recombinant
C. pneumoniae (VR 1310) MOMP as described in.19
Elementary bodies containing the MOMP protein
was used as a positive control. Rabbit pre-immune
serum was used as negative control. The labelling was
visualised with horseradish peroxidase-conjugated
secondary antibody (pork anti-rabbit, DAKO,
Glostrup, Denmark) diluted 1:5000. The bands were
visualised by using enhanced chemiluminescence
(ECL) kit and ECL hyperfilm (Amersham Pharmacia
Biotech, U.K.).
Protein identification
Silver stained protein in question was excised from
the gels and digested in 96-well plates using the proto-
col described by Matthias Mann et al.22 Briefly, the gel0 patients (Lanes 1±20).
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nitrile (1:1) followed by dehydration with acetonitrile.
The proteins were reduced in 10 mM dithiotreitol
(DTT)/50 mM NH4HCO3 for 1 h at 56
C, and alkyl-
ated in 55 mM iodoacetamide/50 mM NH4HCO3 for
2 h at room temp. The gel pieces were washed several
times in 50 mM NH4HCO3 followed by dehydration
with acetonitrile. The proteins were digested over-
night with trypsin (Promega, modified trypsin) at
37 C and the resulting peptide mixtures analysed by
mass spectrometry.
Small aliquots of the generated peptide mixtures
were analysed by MALDI mass spectrometry on
REFLEX III instrument (Bruker Daltonik, Bremen,
Germany). The peptide masses obtained by MALDI
MS were used to query the nrdb sequence database
for protein identification. The nrdb database contains
more than 360 000 entries and is maintained and
updated by EMBL (European Molecular Biology
Laboratory).
Results
Gelelectrophoresis of AAA proteins
The total electrophoretic pattern of AAA proteins was
visualised for each patient by using the highly sensi-
tive silver staining procedure (Fig. 1). Overall, the
distributions of protein bands seemed equally in all
AAA and no appreciable degradation seemed to have
taken place during the sample preparation procedure.
A major band around 15 kDa seemed to be present
in all aneurysms. Furthermore, some bands equally
distributed between 40 kDa and 120 kDa were also
noticed. To determine whether any of these bands
were MOMP, we continued with immunoblotting tests.Fig. 2. Immunoblot analysis of 20 AAA patients (Lanes 1±20). Negat
(Lane B) Chlamydia pneumoniae elementary bodies containing MOMPImmunoblotting
To look for MOMP in the AAA wall immunoblotting
for all 20 patients were performed with anti-MOMP
antibody and is shown in Figure 2. No specific reac-
tion was seen at 40 kDa according to the expected size
of MOMP, but a among very weak unspecific bands
with higher or lower molecular weights than 40 kDa a
very strong specific cross-reacting protein was loca-
lised at the 15 kDa band from all AAA patients. The
fact that the 15 kDa-band was not noticed in the nega-
tive control (lane A), points to a true cross-reaction
due to binding of anti-MOMP antibody to a protein
with a lower molecule weight than the MOMP protein.
No differences between gender, age, current smoking,
diagnose of hypertension and AAA size were noticed.
Protein identification
To identify the strong cross-reaction protein of 15 kDa
a silver stained gel of the aortic wall proteins was
performed, as shown in Figure 1, and the protein in
question was cut out from the gel and subjected to
mass spectrometry. The protein gave 6 peptide
sequences as shown in Table 2, which were all identi-
fied as peptides located in human haemoglobin beta
chain, having and average mass on 15 981 kDa and
a pI of 7.3. The total amino acid coverage was 138±146
giving a 95% sequence identity to haemoglobin beta
chain.
Discussion
We found a positive reaction due to binding of the
anti-MOMP antibody to the AAA wall. The proteinive control (Lane A) represent pre-immune serum. Positive control
protein.
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Table 2. Protein identification by mass spectrometry. The bold sequences are 6 peptides detected by mass spectrometry.
Protein sequence:
VHLTPEEKSA VTALWGKVNV DEVGGEALGR LLVVYPWTQR FFESFGDLST PDAVMGNPKV KAHGKKVLGA FSDGLAHLDN
LKGTFATLSE LHCDKLHVDP ENFRLLGNVL VCVLAHHFGK EFTPPVQAAY QKVVAGVANA LAHKYH
Matching Data:
Measured [Da] Calculated [Da] Diff. [Da] Diff. [ppm] Start End Sequence
932.523 932.520 0.003 2.906 9 17 (K)SAVTALWGK(V)
952.499 952.51 ÿ0.011 ÿ11.269 1 8 VHLTPEEK(S)
1126.569 1126.56 0.005 4.190 96 104 (K)LHVDPENFR(L)
1149.634 1149.674 ÿ0.040 ÿ34.971 133 144 (K)VVAGVANALAHK(Y)
1274.742 1274.72 0.016 12.821 31 40 (R)LLVVYPWTQR(F)
1314.668 1314.665 0.003 2.421 18 30 (K)VNVDEVGGEALGR(L)
1378.686 1378.700 ÿ0.014 ÿ10.120 121 132 (K)EFTPPVQAAYQK(V)
1478.655 1478.694 ÿ0.040 ÿ26.871 83 95 (K)GTFATLSELHCDK(L)
1669.829 1669.891 ÿ0.062 ÿ37.330 67 82 (K)VLGAFSDGLAHLDNLK(G)
1776.954 1776.994 ÿ0.040 ÿ22.780 105 120 (R)LLGNVLVCVLAHHFGK(E)
1797.952 1797.986 ÿ0.034 ÿ18.843 66 82 (K)KVLGAFSDGLAHLDNLK
2058.909 2058.948 ÿ0.039 ÿ18.912 41 59 (R)FFESFGDLSTPDAVMGNPK
2586.237 2586.241 ÿ0.004 ÿ1.527 83 10 GTFATLSELHCDKLHVDPENFR
Da: Dalton, ppm: parts per million.
84 S. Vammen et al.analysis demonstrated that the protein was the beta
chain in human haemoglobin and not MOMP.
When taking a biopsy from the aneurysm wall, it is
difficult to ensure the sample is representative. There-
fore, we chose to harvest biopsies in a standardised
way, from the central part of the anterior wall of all
AAA. The samples were stored at ÿ22 C for up to 3
years, which do not inhibit all biochemical processes.
However, proteins are quite stable at this temperature,
and if the MOMP protein was present in a fragmented
way, it would still have reacted with the antibody, but
at a lighter weight, and would have been recognised
at the protein identification. Our anti-MOMP antibody
was not purified, but the reactions were confirmed by
use of negative and positive controls. We were not
able to demonstrate C. pneumoniae antigen in our sam-
ples, but our immunoblotting results showed, a band
with a lower molecule weight than the MOMP protein
in all AAA samples, due to binding of the anti-MOMP
antibody. If the antibody just was applied in immuno-
histochemistry procedures or to the dissolved wall-
tissue, they would have been positive, but by applying
electrophoresis we could see the positivity was due to
a molecule weight as MOMP protein, but due to a
more light protein. This could, however, be due to
fragmented MOMP, but protein identification demon-
strated that the protein was the human haemoglobin
beta chain.
The PCR test is a diagnostic method for C. pneumo-
niae infection, which claims to yield data of high sen-
sitivity compared to other methods, including culture.
Although, the assumed high sensitivity by PCR pro-
cedure, the test will always depend on atherectomy
samples, and the technique cannot differentiateEur J Vasc Endovasc Surg Vol 24, July 2002between replicating and non-replicating C. pneumo-
niae, which could be useful, as intact pathogens
should be susceptible to antimicrobial therapy. In
order to validate the PCR technique between different
laboratories Apfalter et al. showed that attempts
to directly detect intravascular C. pneumoniae DNA
varies between 0±100%.16 The reasons for this dis-
crepancy can be contaminated samples since several
laboratories reported positive findings in the negative
controls.
Apparently, immunohistostaining procedures yield
more positive results for C. pneumoniae than DNA-
based techniques, but the test also have a poor corre-
lation with PCR-findings. Karlsson et al.23 concluded
in a case control study by immunohistochemical
analysis, culture for C. pneumoniae, PCR and MIF
tests, that C. pneumoniae is often present in a variable
form and that C. pneumoniae is linked to the pathogen-
esis of AAA. However, 75% (20/26) of their patients
with an AAA were positive by the immunohistochem-
ical test, but only 50% (10/20) of these positive tests
could be confirmed by culture, and only 35% (5/14) of
the same patients were positive by PCR, suggesting
serious methodological problems in their tests. Also,
the reasons for this discrepancy are not clear, but
immunohistostaining could be positive, as our study
suggests, due to crossreacting proteins. Like the PCR
test, the immunohistostaining test also depends on the
atherectomy samples, and when taking a biopsy from
the aneurysm wall it may be difficult to ensure, that
the sample is representative, because local differences
in the distribution of C. pneumoniae seems possible.
Wissler et al.,24 also demonstrated potentially
decreased specificity of immunological detection
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atheromatous lesions. Furthermore, not all investiga-
tors use the same antigens and strains and these dif-
ferences in interpretation may make it difficult to
compare the results obtained by different laboratories.
Tambiah et al.25 showed in an animal model, that
C. pneumoniae seems to stimulate the influx of macro-
phages and dilatation of the abdominal aorta. We have
in earlier studies1,8 showed, that AAA expansion was
positively correlated with the presence of indicators of
C. pneumoniae infection, and in a intervention study,26
we demonstrated a positive effect of macrolides on
AAA expansion rates. However, it is still not proven,
that infection with C. pneumoniae causes formation of
AAA in human. Furthermore, macrolides in general
do possess anti-inflammatory properties, which may
explain the protective effect on AAA.
In conclusion, there seems to be a link between
C. pneumoniae infection and AAA expansion rates.
However the final role is not clear. There still is several
methodological problems, and direct detection of
C. pneumoniae by immunohistostaining should be
interpreted with caution due to potential crossreaction
with non chlamydial proteins.
Acknowledgements
The authors thank Kirsten Peterslund for expert technical assistance.
We thank Professor Gunna Christiansen for the anti-MOMP anti-
body K116, preimmune serum and Chlamydia pneumoniae (EB).
Financial support for this study was provided by; The Danish
Heart Foundation, The Foundation of Asta and Rosa Jensen, Danish
Medical Research Council, The University of Aarhus Research
Foundation, The Novo Nordic Foundation and the Health Depart-
ment of Viborg County.
References
1 Lindholt JS, Juul S, Vammen S, Lind I, Fasting H,
Henneberg EW. Immunoglobulin A antibodies against Chlamy-
dia pneumoniae are associated with expansion of abdominal aortic
aneurysm. Br J Surg 1999; 86: 634±638.
2 Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae
infection with other risk factors of atherosclerosis. Am Heart J
1999; 138: S504±S506.
3 Leinonen M, Saikku P. Infections and atherosclerosis. Scand
Cardiovasc J 2000; 34: 12±20.
4 Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD,
Wang SP et al. Past infection by Chlamydia pneumoniae strain
TWAR and asymptomatic carotid atherosclerosis. Atherosclero-
sis Risk in Communities (ARIC) Study Investigators. Am J Med
1993; 95: 499±504.
5 Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS,
Makela PH et al. Serological evidence of an association of a
novel Chlamydia, TWAR, with chronic coronary heart disease
and acute myocardial infarction. Lancet 1988; 2: 983±986.6 Saikku P. Epidemiologic association of Chlamydia pneumoniae
and atherosclerosis: the initial serologic observation and more.
J Infect Dis 2000; 181 S411±S413.
7 Saikku P. Chlamydia pneumoniae in atherosclerosis. J Intern Med
2000; 247: 391±396.
8 Lindholt JS, Ashton HA, Scott RA. Indicators of infection
with Chlamydia pneumoniae are associated with expansion of
abdominal aortic aneurysms. J Vasc Surg 2001; 34: 212±215.
9 Campbell LA, Kuo CC, Grayston JT. Structural and antigenic
analysis of Chlamydia pneumoniae. Infect Immun 1990; 58: 93±97.
10 Grayston JT, Kuo CC, Coulson AS, Campbell LA,
Lawrence RD, Lee MJ et al. Chlamydia pneumoniae (TWAR) in
atherosclerosis of the carotid artery. Circulation 1995; 92: 3397±
3400.
11 Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL,
Grayston JT. Demonstration of Chlamydia pneumoniae in athero-
sclerotic lesions of coronary arteries. J Infect Dis 1993; 167:
841±849.
12 Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of
Chlamydia pneumoniae in aortic lesions of atherosclerosis
by immunocytochemical stain. Arterioscler Thromb 1993; 13:
1501±1504.
13 Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-
Robinson D. Detection and widespread distribution of
Chlamydia pneumoniae in the vascular system and its possible
implications. J Clin Pathol 1996; 49: 102±106.
14 Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae
in coronary arterial fatty streaks and atheromatous plaques. S Afr
Med J 1992; 82: 158±161.
15 Danesh J, Whincup P, Walker M, Lennon L, Thomson A,
Appleby P et al. Chlamydia pneumoniae IgG titres and coronary
heart disease: prospective study and meta-analysis. BMJ 2000;
321: 208±213.
16 Apfalter P, Blasi F, Boman J, Gaydos CA, Kundi M, Maass M
et al. Multicenter Comparison Trial of DNA Extraction Methods
and PCR Assays for Detection of Chlamydia pneumoniae in Endar-
terectomy Specimens. J Clin Microbiol 2001; 39: 519±524.
17 Grayston JT. Background and current knowledge of Chlamydia
pneumoniae and atherosclerosis. J Infect Dis 2000; 181: S402±S410.
18 Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endo-
vascular presence of viable Chlamydia pneumoniae is a common
phenomenon in coronary artery disease. J Am Coll Cardiol 1998;
31: 827±832.
19 Christiansen G, Boesen T, Hjerno K, Daugaard L, Mygind P,
Madsen AS et al. Molecular biology of Chlamydia pneumoniae
surface proteins and their role in immunopathogenicity.
Am Heart J 1999; 138: S491±S495.
20 Bradford MM. A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the principle of
protein-dye binding. Anal Biochem 1976; 72: 248±254.
21 Tunon P, Johansson KE. Yet another improved silver staining
method for the detection of proteins in polyacrylamide gels.
J Biochem Biophys Methods 1984; 9: 171±179.
22 Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectro-
metric sequencing of proteins silver-stained polyacrylamide
gels. Anal Chem 1996; 68: 850±858.
23 Karlsson L, Gnarpe J, Naas J, Olsson G, Lindholm J, Steen B
et al. Detection of viable Chlamydia pneumoniae in abdominal
aortic aneurysms. Eur J Vasc Endovasc Surg 2000; 19: 630±635.
24 Wissler RW. Significance of Chlamydia pneumoniae (TWAR) in
atherosclerotic lesions. Circulation 1995; 92: 3376.
25 Tambiah J, Franklin IJ, Trendell-Smith N, Peston D,
Powell JT. Provocation of experimental aortic inflammation
and dilatation by inflammatory mediators and Chlamydia
pneumoniae. Br J Surg 2001; 88: 935±940.
26 Vammen S, Lindholt JS, Ostergaard L, Fasting H,
Henneberg EW. Randomized double-blind controlled trial of
roxithromycin for prevention of abdominal aortic aneurysm
expansion. Br J Surg 2001; 88: 1066±1072.
Accepted 27 March 2002Eur J Vasc Endovasc Surg Vol 24, July 2002
